Other Clinical Trial - Arbekacin Treatment of Adult Patients With

Clinical Trial Description

The primary purpose of this protocol is to make arbekacin available for treatment of patients with infections caused by multidrug-resistant organisms when treatment with other antibiotics cannot be used due to unavailability, intolerance, contraindications, or treatment non-response. ;

Study Design

Related Conditions & MeSH terms

Communicable Diseases
Infection
Infection Due to Resistant Organism

See also
	Status	Clinical Trial	Phase
	Withdrawn	`NCT02816437` - FMT for MDRO Colonization in Solid Organ Transplant	Phase 1
	Terminated	`NCT02922816` - FMT for MDRO Colonization After Infection in Renal Transplant Recipients	Phase 1

See also

Status

Clinical Trial

Phase

Withdrawn

NCT02816437 - FMT for MDRO Colonization in Solid Organ Transplant

Phase 1

Terminated

NCT02922816 - FMT for MDRO Colonization After Infection in Renal Transplant Recipients

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01659515
Study type	Expanded Access
Source	U.S. Army Medical Research and Development Command
Contact
Status	No longer available
Phase

Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms